Effect of Tocilizumab on Mortality in Patients with SARS-CoV-2 Pneumonia Caused by Delta or Omicron Variants: A Propensity-Matched Analysis in Nimes University Hospital, France

We aimed to assess the factors associated with mortality in patients treated with tocilizumab for a SARS-CoV-2 pneumonia due to the delta or omicron variants of concern (VOC) and detect an effect of tocilizumab on mortality. We conducted a prospective cohort study in a tertiary hospital from 1 August 2021 to 31 March 2022 including patients with severe COVID-19, treated with tocilizumab. Factors associated with mortality were assessed in a Cox model; then, the 60-day mortality rates of COVID-19 patients treated with standard of care (SoC) +/- tocilizumab were compared after 1:1 propensity score matching. The mortality rate was 22% (N = 26/118) and was similar between delta and omicron cases ( = 0.6). The factors independently associated with mortality were age (HR 1.06; 95% CI (1.02-1.11), = 0.002), Charlson index (HR 1.33; 95% CI (1.11-1.6), = 0.002), WHO-CPS (HR 2.56; 95% CI (1.07-6.22) = 0.03), and tocilizumab infusion within the first 48 h following hospital admission (HR 0.37, 95% CI (0.14-0.97), = 0.04). No significant differences in mortality between the tocilizumab plus SoC and SoC alone groups ( = 0.5) were highlighted. However, the patients treated with tocilizumab within the 48 h following hospital admission had better survival ( = 0.04). In conclusion, our results suggested a protective effect on mortality of the early administration of tocilizumab in patients with severe COVID-19 regardless of the VOC involved.